SK5582002A3 - A medicament for treating or preventing diseases caused by ischaemic conditions - Google Patents

A medicament for treating or preventing diseases caused by ischaemic conditions Download PDF

Info

Publication number: SK5582002A3
Authority: SK; Slovakia
Prior art keywords: medicament; formula; manufacture; compound; use according
Prior art date: 1999-10-27

Application number

SK558-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Andreas Weichert

Udo Albus

Hans-Willi Jansen

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-27

Filing date

2000-10-14

Publication date

2002-08-06

2000-10-14 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2002-08-06 Publication of SK5582002A3 publication Critical patent/SK5582002A3/sk

Links

239000003814 drug Substances 0.000 title claims abstract description 35
230000000302 ischemic effect Effects 0.000 title claims abstract description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 14
201000010099 disease Diseases 0.000 title claims description 12
150000003839 salts Chemical class 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 40
238000004519 manufacturing process Methods 0.000 claims description 21
238000011282 treatment Methods 0.000 claims description 15
238000011321 prophylaxis Methods 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 10
238000002560 therapeutic procedure Methods 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 6
239000000460 chlorine Substances 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 6
229910052731 fluorine Inorganic materials 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
210000000056 organ Anatomy 0.000 claims description 6
230000004663 cell proliferation Effects 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 3
230000002093 peripheral effect Effects 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
238000001356 surgical procedure Methods 0.000 claims description 3
206010002383 Angina Pectoris Diseases 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
238000003860 storage Methods 0.000 claims description 2
208000006011 Stroke Diseases 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
210000001428 peripheral nervous system Anatomy 0.000 claims 1
238000004321 preservation Methods 0.000 claims 1
238000002054 transplantation Methods 0.000 claims 1
GQRRWNLARRRPRY-UHFFFAOYSA-N 1,4-dihydroquinazolin-2-amine Chemical class C1=CC=C2CNC(N)=NC2=C1 GQRRWNLARRRPRY-UHFFFAOYSA-N 0.000 abstract description 2
239000011734 sodium Substances 0.000 description 15
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
230000002265 prevention Effects 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
201000001320 Atherosclerosis Diseases 0.000 description 8
239000002904 solvent Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
206010048554 Endothelial dysfunction Diseases 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000008694 endothelial dysfunction Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
208000035150 Hypercholesterolemia Diseases 0.000 description 4
208000031226 Hyperlipidaemia Diseases 0.000 description 4
239000000969 carrier Substances 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010020880 Hypertrophy Diseases 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 3
229960002576 amiloride Drugs 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
-1 for example Substances 0.000 description 3
230000000055 hyoplipidemic effect Effects 0.000 description 3
230000007574 infarction Effects 0.000 description 3
230000004941 influx Effects 0.000 description 3
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 3
229960003343 ouabain Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
206010003225 Arteriospasm coronary Diseases 0.000 description 2
208000003890 Coronary Vasospasm Diseases 0.000 description 2
208000007530 Essential hypertension Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000036523 atherogenesis Effects 0.000 description 2
230000000923 atherogenic effect Effects 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
NTAZDTNWTTWHOM-UHFFFAOYSA-N bis[2-(2-aminophenyl)-3,4-dimethoxyphenyl]methanone Chemical compound C=1C=CC=C(N)C=1C1=C(OC)C(OC)=CC=C1C(=O)C1=CC=C(OC)C(OC)=C1C1=CC=CC=C1N NTAZDTNWTTWHOM-UHFFFAOYSA-N 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
201000011634 coronary artery vasospasm Diseases 0.000 description 2
239000012043 crude product Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005048 flame photometry Methods 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
238000000034 method Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000008569 process Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
VSJQWMNZEHXCIX-WXXKFALUSA-N (e)-but-2-enedioate;4-(3,4-dimethoxyphenyl)-1,4-dihydroquinazolin-3-ium-2-amine Chemical compound [O-]C(=O)\C=C\C([O-])=O.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1 VSJQWMNZEHXCIX-WXXKFALUSA-N 0.000 description 1
CUMPLAGDCOPAEA-WXXKFALUSA-N (e)-but-2-enedioate;4-(3,4-dimethoxyphenyl)-3-methyl-1,4-dihydroquinazolin-3-ium-2-amine Chemical compound [O-]C(=O)\C=C\C([O-])=O.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1C.C1=C(OC)C(OC)=CC=C1C1C2=CC=CC=C2[NH+]=C(N)N1C CUMPLAGDCOPAEA-WXXKFALUSA-N 0.000 description 1
LGACUMPRRMLUFZ-UHFFFAOYSA-N 1,4-dihydroquinazoline Chemical compound C1=CC=C2CN=CNC2=C1 LGACUMPRRMLUFZ-UHFFFAOYSA-N 0.000 description 1
FJTWNDHPJHKMIY-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1,4-dihydroquinazolin-2-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1C2=CC=CC=C2N=C(N)N1 FJTWNDHPJHKMIY-UHFFFAOYSA-N 0.000 description 1
MMUWGLDSHWYPFG-UHFFFAOYSA-N 4-phenyl-1,4-dihydroquinazolin-2-amine Chemical compound N1C(N)=NC2=CC=CC=C2C1C1=CC=CC=C1 MMUWGLDSHWYPFG-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010023421 Kidney fibrosis Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002337 anti-port Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
YWGDXXZQJAMJKF-UHFFFAOYSA-N bis[2-(2-aminophenyl)-4-methoxyphenyl]methanone Chemical compound NC1=C(C=CC=C1)C1=C(C=CC(=C1)OC)C(=O)C1=C(C=C(C=C1)OC)C1=C(C=CC=C1)N YWGDXXZQJAMJKF-UHFFFAOYSA-N 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
244000309464 bull Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000001269 cardiogenic effect Effects 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
230000002727 hyperosmolar Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000004224 protection Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000009441 vascular protection Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK558-2002A 1999-10-27 2000-10-14 A medicament for treating or preventing diseases caused by ischaemic conditions SK5582002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19951702A DE19951702A1 (de)	1999-10-27	1999-10-27	Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
PCT/EP2000/010127 WO2001030328A2 (de)	1999-10-27	2000-10-14	Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten

Publications (1)

Publication Number	Publication Date
SK5582002A3 true SK5582002A3 (en)	2002-08-06

Family

ID=7927021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK558-2002A SK5582002A3 (en)	1999-10-27	2000-10-14	A medicament for treating or preventing diseases caused by ischaemic conditions

Country Status (27)

Country	Link
US (1)	US6331546B1 (cs)
EP (1)	EP1244454B1 (cs)
JP (1)	JP2003512420A (cs)
KR (1)	KR20020041831A (cs)
CN (1)	CN1181822C (cs)
AR (1)	AR026242A1 (cs)
AT (1)	ATE324111T1 (cs)
AU (1)	AU7664800A (cs)
BR (1)	BR0014985A (cs)
CA (1)	CA2388965A1 (cs)
CZ (1)	CZ20021414A3 (cs)
DE (2)	DE19951702A1 (cs)
EE (1)	EE200200215A (cs)
HR (1)	HRP20020363A2 (cs)
HU (1)	HUP0203774A3 (cs)
IL (1)	IL149160A0 (cs)
MX (1)	MXPA02004035A (cs)
NO (1)	NO20021710L (cs)
NZ (1)	NZ518588A (cs)
PL (1)	PL356399A1 (cs)
RU (1)	RU2002113667A (cs)
SK (1)	SK5582002A3 (cs)
TR (1)	TR200201141T2 (cs)
TW (1)	TWI227135B (cs)
WO (1)	WO2001030328A2 (cs)
YU (1)	YU30602A (cs)
ZA (1)	ZA200204057B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69927987T2 (de) *	1998-08-13	2006-11-09	Hadasit Medical Research Services & Development Co. Ltd.	Hemmung von mit gewebetrauma verbundenen pathogenen prozessen
DK1453810T3 (da) *	2001-12-05	2009-07-20	Sanofi Aventis Deutschland	Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
DE10163914A1 (de) *	2001-12-22	2003-07-03	Aventis Pharma Gmbh	Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10312963A1 (de) *	2003-03-24	2004-10-07	Aventis Pharma Deutschland Gmbh	Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3560601A (en)	1968-11-25	1971-02-02	Ford Motor Co	Process for manufacturing porous thermoplastic sheet material
IL102764A0 (en) *	1991-08-16	1993-01-31	Merck & Co Inc	Quinazoline derivatives,and pharmaceutical compositions containing them
WO1994007498A1 (fr) *	1992-10-07	1994-04-14	Sumitomo Pharmaceuticals Company, Limited	Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
DE19713427A1 (de) *	1997-04-01	1998-10-08	Hoechst Ag	Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

1999
- 1999-10-27 DE DE19951702A patent/DE19951702A1/de not_active Withdrawn
2000
- 2000-10-14 IL IL14916000A patent/IL149160A0/xx unknown
- 2000-10-14 HR HR20020363A patent/HRP20020363A2/hr not_active Application Discontinuation
- 2000-10-14 HU HU0203774A patent/HUP0203774A3/hu unknown
- 2000-10-14 CN CNB008148872A patent/CN1181822C/zh not_active Expired - Fee Related
- 2000-10-14 NZ NZ518588A patent/NZ518588A/en unknown
- 2000-10-14 CA CA002388965A patent/CA2388965A1/en not_active Abandoned
- 2000-10-14 AU AU76648/00A patent/AU7664800A/en not_active Abandoned
- 2000-10-14 EE EEP200200215A patent/EE200200215A/xx unknown
- 2000-10-14 AT AT00966165T patent/ATE324111T1/de not_active IP Right Cessation
- 2000-10-14 YU YU30602A patent/YU30602A/sh unknown
- 2000-10-14 WO PCT/EP2000/010127 patent/WO2001030328A2/de not_active Ceased
- 2000-10-14 RU RU2002113667/15A patent/RU2002113667A/ru not_active Application Discontinuation
- 2000-10-14 MX MXPA02004035A patent/MXPA02004035A/es active IP Right Grant
- 2000-10-14 EP EP00966165A patent/EP1244454B1/de not_active Expired - Lifetime
- 2000-10-14 BR BR0014985-3A patent/BR0014985A/pt not_active IP Right Cessation
- 2000-10-14 TR TR2002/01141T patent/TR200201141T2/xx unknown
- 2000-10-14 PL PL00356399A patent/PL356399A1/xx unknown
- 2000-10-14 SK SK558-2002A patent/SK5582002A3/sk unknown
- 2000-10-14 DE DE50012667T patent/DE50012667D1/de not_active Expired - Lifetime
- 2000-10-14 JP JP2001532748A patent/JP2003512420A/ja not_active Abandoned
- 2000-10-14 KR KR1020027005359A patent/KR20020041831A/ko not_active Withdrawn
- 2000-10-14 CZ CZ20021414A patent/CZ20021414A3/cs unknown
- 2000-10-24 TW TW089122279A patent/TWI227135B/zh not_active IP Right Cessation
- 2000-10-25 AR ARP000105620A patent/AR026242A1/es unknown
- 2000-10-26 US US09/696,233 patent/US6331546B1/en not_active Expired - Fee Related
2002
- 2002-04-11 NO NO20021710A patent/NO20021710L/no not_active Application Discontinuation
- 2002-05-22 ZA ZA200204057A patent/ZA200204057B/en unknown

Also Published As

Publication number	Publication date
MXPA02004035A (es)	2002-10-11
PL356399A1 (en)	2004-06-28
CN1181822C (zh)	2004-12-29
HUP0203774A3 (en)	2003-07-28
NO20021710D0 (no)	2002-04-11
NO20021710L (no)	2002-04-11
DE50012667D1 (de)	2006-06-01
RU2002113667A (ru)	2004-01-10
US6331546B1 (en)	2001-12-18
YU30602A (sh)	2004-12-31
EP1244454A2 (de)	2002-10-02
JP2003512420A (ja)	2003-04-02
AR026242A1 (es)	2003-02-05
NZ518588A (en)	2004-06-25
ZA200204057B (en)	2003-02-26
ATE324111T1 (de)	2006-05-15
TWI227135B (en)	2005-02-01
CZ20021414A3 (cs)	2002-07-17
BR0014985A (pt)	2003-07-22
WO2001030328A3 (de)	2002-06-20
EE200200215A (et)	2003-06-16
TR200201141T2 (tr)	2002-11-21
WO2001030328A2 (de)	2001-05-03
HK1050480A1 (en)	2003-06-27
HUP0203774A2 (en)	2003-05-28
HRP20020363A2 (en)	2004-02-29
DE19951702A1 (de)	2001-05-03
IL149160A0 (en)	2002-11-10
AU7664800A (en)	2001-05-08
CA2388965A1 (en)	2001-05-03
KR20020041831A (ko)	2002-06-03
CN1384747A (zh)	2002-12-11
EP1244454B1 (de)	2006-04-26

Publication	Publication Date	Title
JP3490739B2 (ja)	2004-01-26	３，４，５−置換ベンゾイルグアニジン、それらの製法ならびにそれらを含有する医薬
KR100360127B1 (ko)	2003-04-23	치환된1-옥소-1,2-디하이드로이소퀴놀리노일구아니딘,1,1-디옥소-2h-1,2-벤조티아지노일구아니딘및이들을함유하는약제
CZ403392A3 (en)	1993-12-15	Amino-substituted benzylguanidines, process of their preparation, their use as medicaments and a medicament containing thereof
JP4039589B2 (ja)	2008-01-30	置換インダニリジンアセチルグアニジン類、それらの製造方法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬
CZ20021414A3 (cs)	2002-07-17	Léčivo k terapii nebo profylaxi chorob podmíněných ischemickými stavy
RU2182901C2 (ru)	2002-05-27	Замещенные 1-нафтоилгуанидины и лекарственное средство на их основе
RU2257205C2 (ru)	2005-07-27	Применение 2-имидазолилзамещенных карбинолов для получения лекарственного средства для лечения или профилактики заболеваний, обусловленных ишемическими состояниями
RU2193025C2 (ru)	2002-11-20	Ортозамещенные бензоилгуанидины и лекарственное средство на их основе
KR100959031B1 (ko)	2010-05-20	치환된 이미다졸리딘, 이의 제조방법 및 치환된 이미다졸리딘을 함유하는 약제
JPH1081662A (ja)	1998-03-31	ビス−オルト−置換されたベンゾイルグアニジン、その製法、医薬または診断剤としてのその使用およびそれを含有する医薬
HK1050480B (en)	2005-05-06	Use of 2-amino-3, 4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions
MXPA97003871A (en)	1998-07-03	Benzoilguanidinas bis-orto-replaced, procedure for its preparation, its employment as a diagnostic medicine or agent, as well as a medication that conti